Skip to main content

Intensive liver care and management of acute hepatic failure

Abstract

In describing acute liver failure, the term fulminant hepatic failure (FHF) is used to denote patients with the most rapid progression, normally defined as the onset of encephalopathy within eight weeks of the onset of symptoms. For patients with a slower onset of encephalopathy, ranging from eight weeks to six months after the onset of symptoms, late-onset hepatic failure is the term used to reflect the overlap in clinical features with some patients with FHF. The importance of accurately determining the type of acute liver failure results from increasing evidence of an inverse relationship between the tempo of disease progression and the chances of recovery. Prognosis is also dependent on the underlying etiology. Principles of management are as follows: (1) an accurate recognition of the tempo of the hepatic failure—fulminant, late onset, acute on chronic—and the establishment of a likely etiology; (2) early detection and treatment of complications, particularly metabolic acidosis (early), renal failure, cerebral edema, and infection (late); (3) optimization of conditions for regeneration by maintenance of a near normal metabolic milieu (with removal of toxins by various methods of artificial liver support if necessary); and (4) early consideration of an orthotopic liver transplant for those patients in the poor prognosis group. Variations in the natural history and clinical features of acute liver failure (ALF) have led to a number of different classifications and subgroupings. Knowledge of these is important in relation to the assessment of prognosis and is even more important now that transplantation is a therapeutic option. Fulminant hepatic failure (FHF) is the term used to denote the subgroup where the tempo is greatest and is variously defined as the onset of encephalopathy within four weeks (1), six weeks (EASL, 1979) and eight weeks [as described by Trey and Davidson (2)] of the onset of symptoms, or within two weeks of the onset of jaundice (3). The patients with a more protracted course are designated by the terms subacute or late-onset hepatic failure (LOHF) (4) or subfulminant hepatic failure (3). The etiology of the hepatic failure also has a major influence on the likely prognosis.

This is a preview of subscription content, access via your institution.

References

  1. Mathieson LR, Skovoj P, Nielson JO, et al: Hepatitis type A, B and non-A, non-B in fulminant hepatitis. Gut 21:72–77, 1980

    Google Scholar 

  2. Trey C, Davidson LS: The management of fulminant hepatic failure,In Progress in Liver Disease. H Popper, F Schaffner (eds). New York, Grune & Stratton, 1970, pp 282–298

    Google Scholar 

  3. Bernuau J, Rueff B, Benhamou J-P: Fulminant and subfulminant liver failure: definitions and causes. Sem Liv Dis 6:97–106, 1986

    Google Scholar 

  4. Gimson AES, O'Grady J, Ede RJ, et al: Late-onset hepatic failure: Clinical serologic and histological features. Hepatology 6:228, 294, 1986

    Google Scholar 

  5. Smedile A, Farci P, Verme G, et al: Influence of delta infection on severity of hepatitis B. Lancet 2:945–947, 1982

    Google Scholar 

  6. Govindarajan S, Chin KP, Redeker AG, Peters RL: Fulminant B viral hepatitis: Role of delta agent. Gastroenterology 86:1417–1420, 1984

    Google Scholar 

  7. Gimson AES, Tedder RS, White YS, et al: Serological markers in fulminant hepatitis B. Gut 24:615–617, 1983

    Google Scholar 

  8. Brechot C, Bernuau J, Thiers V, et al: Multiplication of hepatitis B virus in fulminant hepatitis B. Br Med J 288:270–271, 1984

    Google Scholar 

  9. Papaevangelou G, Tassaopoulos N, Roumeliotou-Karayannis A, Richardson C: Etiology of fulminant viral hepatitis in Greece. Hepatology 4:369–372, 1984

    Google Scholar 

  10. Dienstag JL: Non-A, non-B hepatitis. I. Recognition, epidemiology and clinical features. Gastroenterology 85:439–462, 1983

    Google Scholar 

  11. O'Grady JG, Gimson AES, O'Brien CJ, et al: Controlled trials of charcoal haemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 94:1186–1192, 1988

    Google Scholar 

  12. O'Grady JG, Langley PG, Isola LM, et al: Coagulopathy of fulminant hepatic failure. Sem Liv Dis 6:159–163, 1986

    Google Scholar 

  13. Ede RJ, Gimson AES, Bihari D, Williams R: Controlled hyperventilation in the prevention of cerebral oedema in fulminant hepatic failure. J Hepatol 2:43–51, 1986

    Google Scholar 

  14. Canalese J, Gimson AES, Davis C, et al: Controlled trial of dexamethasone and mannitol for the cerebral oedema of FHF. Gut 23:625–630, 1982

    Google Scholar 

  15. Wilkinson SP, Weston MJ, Parsons V, Williams R: Dialysis in the treatment of renal failure in patients with liver disease.

  16. Bihari DJ, Gimson AES, Williams R: Cardiovascular, pulmonary and renal complications of fulminant hepatic failure. Sem Liv Dis 6:119–128, 1986

    Google Scholar 

  17. Macdougall BRD, Williams R: H2 receptor antagonist in the prevention of acute upper gastrointestinal hemorrhage in fulminant hepatic failure. Gastroenterology 74:164–165, 1978

    Google Scholar 

  18. Gazzard BG, Henderson JM, Williams R: Early changes in coagulation following a paracetamol overdose and a controlled trial of fresh frozen plasma therapy. Gut 16:617–620, 1975

    Google Scholar 

  19. Rolando N, Alexander GJM, Harvey F, Brahm J: Prospective study of bacterial infection in acute liver failure: An analysis of 50 patients. Hepatology 2:49–53, 1990

    Google Scholar 

  20. Rolando N, Harvey F, Brahm J, et al: Fungal infection: A common, unrecognized complication of acute liver failure. J Hepatol 12:1–9, 1991

    Google Scholar 

  21. Takahashi Y: Acute hepatic failure—in special relation to treatment. Jpn J Med 22:140–145, 1983

    Google Scholar 

  22. Lewis S, Hahn T: Interferon deficiency syndrome. Clin Exp Immunol 60:267–273, 1985

    Google Scholar 

  23. Sanchez-Tapias J, Mas A, Costa J, et al: Recombinant a2c-interferon therapy in fulminant viral hepatitis. J Hepatol 5:205–210, 1987

    Google Scholar 

  24. Gimson AES, Braude S, Mellon PJ, et al: Earlier charcoal haemoperfusion in fulminant hepatic failure. Lancet 2:681–683, 1982

    Google Scholar 

  25. Berk PD, Goldberg JD: Charcoal haemoperfusion: Plus ca change, plus c'est la même chose. Gastroenterology 94:1228, 1988 (editorial)

    Google Scholar 

  26. O'Grady JG, Alexander GJM, Hayllar KM, Williams R: Early indicators of prognosis in acute liver failure and their application to selection of patients for orthotopic liver transplantation. Gastroenterology 1989 97:439–445, 1989

    Google Scholar 

  27. Peleman RR, Gavaler JS, Van Thiel D, et al: Orthotopic liver transplantation for acute and subacute hepatic failure in adults. Hepatology 7:484–489, 1987

    Google Scholar 

  28. Bismuth H, Samuel D, Gugenheim, et al: Emergency liver transplantation for fulminant hepatitis. Ann Intern Med 107:337–341, 1987

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Williams, R., Gimson, A.E.S. Intensive liver care and management of acute hepatic failure. Digest Dis Sci 36, 820–826 (1991). https://doi.org/10.1007/BF01311243

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01311243

Key Words